Adverum Biotechnologies Inc Working Capital to Net Assets Ratio
Adverum Biotechnologies Inc working capital to net assets ratio. Adverum Biotechnologies Inc (ADVM) has a Working Capital to Net Assets ratio of 28.5% as of September 2025. Working capital of $-15.84 Million (current assets of $28.91 Million minus current liabilities of $44.75 Million) is measured against net assets of $-55.65 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ADVM goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Adverum Biotechnologies Inc (2012–2024)
Working capital to net assets ratio of Adverum Biotechnologies Inc from 2012 to 2024. This chart shows how Adverum Biotechnologies Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 28.5%, reflecting working capital of $-15.84 Million against net assets of $-55.65 Million USD. See ADVM defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Adverum Biotechnologies Inc Working Capital to Net Assets Ratio by Year (2012–2024)
Adverum Biotechnologies Inc working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Adverum Biotechnologies Inc from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Adverum Biotechnologies Inc balance sheet assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 153.3% | $108.40 Million | $70.71 Million | $131.30 Million | $22.90 Million | ▲ +30.1 pp |
| 2023 | 123.2% | $82.79 Million | $67.22 Million | $102.77 Million | $19.98 Million | ▲ +35.9 pp |
| 2022 | 87.2% | $158.35 Million | $181.52 Million | $190.59 Million | $32.25 Million | ▼ -6.3 pp |
| 2021 | 93.6% | $295.82 Million | $316.19 Million | $317.14 Million | $21.32 Million | ▼ -1.7 pp |
| 2020 | 95.2% | $413.57 Million | $434.35 Million | $434.44 Million | $20.87 Million | ▲ +5.8 pp |
| 2019 | 89.4% | $156.46 Million | $174.96 Million | $175.87 Million | $19.41 Million | ▼ -9.0 pp |
| 2018 | 98.4% | $198.03 Million | $201.17 Million | $208.75 Million | $10.72 Million | ▼ -1.0 pp |
| 2017 | 99.5% | $183.07 Million | $184.03 Million | $193.74 Million | $10.67 Million | ▼ -0.4 pp |
| 2016 | 99.9% | $215.38 Million | $215.60 Million | $225.27 Million | $9.90 Million | ▼ -0.8 pp |
| 2015 | 100.7% | $254.42 Million | $252.59 Million | $260.99 Million | $6.57 Million | ▼ -2.8 pp |
| 2014 | 103.6% | $154.81 Million | $149.48 Million | $160.28 Million | $5.47 Million | ▼ -52.4 pp |
| 2013 | 156.0% | $-340.00K | $-218.00K | $822.00K | $1.16 Million | ▲ +110.1 pp |
| 2012 | 45.8% | $-457.00K | $-997.00K | $382.00K | $839.00K | — |